PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
22.25%
Revenue growth above 1.5x AVGO's 2.54%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
30.11%
Gross profit growth above 1.5x AVGO's 3.45%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
114.75%
EBIT growth above 1.5x AVGO's 7.65%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
114.75%
Operating income growth above 1.5x AVGO's 7.65%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
114.79%
Net income growth above 1.5x AVGO's 25.65%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
116.00%
EPS growth above 1.5x AVGO's 25.71%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
112.00%
Diluted EPS growth above 1.5x AVGO's 27.27%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.32%
Share count expansion well above AVGO's 0.49%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.64%
Diluted share change of 0.64% while AVGO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-0.32%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-18.38%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-40.30%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
423.15%
10Y revenue/share CAGR at 50-75% of AVGO's 571.10%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
217.61%
5Y revenue/share CAGR above 1.5x AVGO's 71.79%. David Dodd would look for consistent product or market expansions fueling outperformance.
74.94%
3Y revenue/share CAGR above 1.5x AVGO's 39.71%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
463.12%
10Y OCF/share CAGR at 50-75% of AVGO's 892.55%. Martin Whitman might fear a structural deficiency in operational efficiency.
339.89%
5Y OCF/share CAGR 1.25-1.5x AVGO's 253.40%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
7.86%
3Y OCF/share CAGR under 50% of AVGO's 64.46%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
1370.70%
Net income/share CAGR above 1.5x AVGO's 677.82% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
376.30%
5Y net income/share CAGR at 50-75% of AVGO's 705.04%. Martin Whitman might see a shortfall in operational efficiency or brand power.
55.56%
3Y net income/share CAGR 75-90% of AVGO's 63.70%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
394.32%
10Y equity/share CAGR at 50-75% of AVGO's 677.98%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
201.19%
5Y equity/share CAGR above 1.5x AVGO's 20.26%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
135.54%
Positive short-term equity growth while AVGO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
63.82%
Below 50% of AVGO's 608.75%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
15.00%
Below 50% of AVGO's 115.37%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
22.17%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
6.71%
Inventory shrinking or stable vs. AVGO's 15.54%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
6.76%
Asset growth above 1.5x AVGO's 0.47%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
9.85%
BV/share growth above 1.5x AVGO's 1.18%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.69%
We’re deleveraging while AVGO stands at 0.05%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
5.02%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-17.86%
We cut SG&A while AVGO invests at 6.46%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.